Article
Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis.
EBioMedicine - 1 Apr 2024
Ernst Sophie M, Hofman Maaike M, van der Horst Tessa E, Paats Marthe S, Heijboer Frank W J, Aerts Joachim G J V, Dumoulin Daphne W, Cornelissen Robin, von der Thüsen Jan H, de Bruijn Peter, Hoop Esther Oomen-de, Mathijssen Ron H J, Koolen Stijn L W, Dingemans Anne-Marie C
Abstract excerpt
BACKGROUND: Sotorasib given after immunotherapy could put patients at increased risk of hepatotoxicity. Therefore, there is a need to gain insight into the potential correlation between anti-PD-(L)1 treatment, anti-PD-(L)1 concentrations, sotorasib concentrations, and the incidence of hepatotoxicity during sotorasib. METHODS: Patients with KRASG12C-mutated NSCLC treated with sotorasib were prospectively enrolled...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.